Tag Archives: Could

Could proxy advisors sway investors to vote ‘no’ on BMS-Celgene merger?

After Bristol-Myers Squibb and activist investor Starboard Value released dueling presentations on the planned $ 74 billion merger with Celgene earlier this week, Wall Street analysts started speculating about what might actually cause the deal to go south. Credit Suisse analyst Vamil Divan raised one possibility: proxy advisory firms. They usually issue recommendations to shareholders… Read More »